Cargando…
Percutaneous Transcatheter Closure of Congenital Ventricular Septal Defects
Ventricular septal defects (VSDs) are the most common kind of congenital heart disease and, if indicated, surgical closure has been accepted as a gold-standard treatment. However, as less-invasive methods are preferred, percutaneous device closure has been developed. After the first VSD closure was...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Society of Cardiology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011220/ https://www.ncbi.nlm.nih.gov/pubmed/36914603 http://dx.doi.org/10.4070/kcj.2022.0336 |
_version_ | 1784906342328172544 |
---|---|
author | Song, Jinyoung |
author_facet | Song, Jinyoung |
author_sort | Song, Jinyoung |
collection | PubMed |
description | Ventricular septal defects (VSDs) are the most common kind of congenital heart disease and, if indicated, surgical closure has been accepted as a gold-standard treatment. However, as less-invasive methods are preferred, percutaneous device closure has been developed. After the first VSD closure was performed percutaneously by Lock in 1988, both techniques and devices have developed consistently. A perventricular approach for closure of muscular VSD in small patients and the closure of perimembranous VSD using off-label devices are key remarkable developments. Even though the Amplatzer membranous VSD occluder (Abbott) could not be approved for use due to the high complete atrioventricular conduction block rate, other new devices have shown good results for closure of perimembranous VSDs. However, the transcatheter technique is slightly complicated to perform, and concerns about conduction problems after VSD closure with devices remain. There have been a few reports demonstrating successful closure of subarterial-type VSDs with Amplatzer devices, but long-term issues involving aortic valve damage have not been explored yet. In conclusion, transcatheter VSD closure should be accepted as being as effective and safe as surgery but should only be performed by experienced persons and in specialized institutes because the procedure is complex and requires different techniques. To avoid serious complications, identifying appropriate patient candidates for device closure before the procedure is very important. |
format | Online Article Text |
id | pubmed-10011220 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | The Korean Society of Cardiology |
record_format | MEDLINE/PubMed |
spelling | pubmed-100112202023-03-15 Percutaneous Transcatheter Closure of Congenital Ventricular Septal Defects Song, Jinyoung Korean Circ J State of the Art Review Ventricular septal defects (VSDs) are the most common kind of congenital heart disease and, if indicated, surgical closure has been accepted as a gold-standard treatment. However, as less-invasive methods are preferred, percutaneous device closure has been developed. After the first VSD closure was performed percutaneously by Lock in 1988, both techniques and devices have developed consistently. A perventricular approach for closure of muscular VSD in small patients and the closure of perimembranous VSD using off-label devices are key remarkable developments. Even though the Amplatzer membranous VSD occluder (Abbott) could not be approved for use due to the high complete atrioventricular conduction block rate, other new devices have shown good results for closure of perimembranous VSDs. However, the transcatheter technique is slightly complicated to perform, and concerns about conduction problems after VSD closure with devices remain. There have been a few reports demonstrating successful closure of subarterial-type VSDs with Amplatzer devices, but long-term issues involving aortic valve damage have not been explored yet. In conclusion, transcatheter VSD closure should be accepted as being as effective and safe as surgery but should only be performed by experienced persons and in specialized institutes because the procedure is complex and requires different techniques. To avoid serious complications, identifying appropriate patient candidates for device closure before the procedure is very important. The Korean Society of Cardiology 2023-02-06 /pmc/articles/PMC10011220/ /pubmed/36914603 http://dx.doi.org/10.4070/kcj.2022.0336 Text en Copyright © 2023. The Korean Society of Cardiology https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | State of the Art Review Song, Jinyoung Percutaneous Transcatheter Closure of Congenital Ventricular Septal Defects |
title | Percutaneous Transcatheter Closure of Congenital Ventricular Septal Defects |
title_full | Percutaneous Transcatheter Closure of Congenital Ventricular Septal Defects |
title_fullStr | Percutaneous Transcatheter Closure of Congenital Ventricular Septal Defects |
title_full_unstemmed | Percutaneous Transcatheter Closure of Congenital Ventricular Septal Defects |
title_short | Percutaneous Transcatheter Closure of Congenital Ventricular Septal Defects |
title_sort | percutaneous transcatheter closure of congenital ventricular septal defects |
topic | State of the Art Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011220/ https://www.ncbi.nlm.nih.gov/pubmed/36914603 http://dx.doi.org/10.4070/kcj.2022.0336 |
work_keys_str_mv | AT songjinyoung percutaneoustranscatheterclosureofcongenitalventricularseptaldefects |